探討腸道外營養液魚油(Omegaven)治療肝損傷的效果

注册号:

Registration number:

ChiCTR-TRC-08000718 

最近更新日期:

Date of Last Refreshed on:

2015-06-02 21:47:48 

注册时间:

Date of Registration:

2008-03-31 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

探討腸道外營養液魚油(Omegaven)治療肝損傷的效果

Public title:

A randomised, double-blind, controlled study of Omegaven for rescue treatment of parenteral nutrition-associated cholestasis (PNAC) in infants requiring long-term parenteral nutrition

注册题目简写:

English Acronym:

研究课题的正式科学名称:

探討腸道外營養液魚油(Omegaven)治療肝損傷的效果

Scientific title:

A randomised, double-blind, controlled study of Omegaven for rescue treatment of parenteral nutrition-associated cholestasis (PNAC) in infants requiring long-term parenteral nutrition

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

CUHK_CCT00161

申请注册联系人:

Lam, Hugh Simon Hung San 

研究负责人:

Lam, Hugh Simon Hung San 

Applicant:

Lam, Hugh Simon Hung San 

Study leader:

Lam, Hugh Simon Hung San 

申请注册联系人电话:

Applicant telephone:

+852 26322211

研究负责人电话:

Study leader's
telephone:

+852 26322211

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

hshslam@cuhk.edu.hk

研究负责人电子邮件:

Study leader's E-mail:

hshslam@cuhk.edu.hk

申请单位网址(自愿提供):

Applicant website(voluntary supply):

http://www.cct.cuhk.edu.hk/registry/publictrialrecord.aspx?trialid=CUHK_CCT00161

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

http://www.cct.cuhk.edu.hk/registry/publictrialrecord.aspx?trialid=CUHK_CCT00161

申请注册联系人通讯地址:

Department of Paediatrics, 6/F Clinical Sciences Building, PWH

研究负责人通讯地址:

Department of Paediatrics, 6/F Clinical Sciences Building, PWH

Applicant address:

Department of Paediatrics, 6/F Clinical Sciences Building, PWH

Study leader's address:

Department of Paediatrics, 6/F Clinical Sciences Building, PWH

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

Chinese University of Hong Kong

Applicant's institution:

Chinese University of Hong Kong

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

NA

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Chinese University of Hong Kong

Name of the ethic committee:

Chinese University of Hong Kong

伦理委员会批准日期:

Date of approved by ethic committee:

2013-08-26 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

Department of Paediatrics, CUHK

Primary sponsor:

Department of Paediatrics, CUHK

研究实施负责(组长)单位地址:

Department of Paediatrics, 6/F Clinical Sciences Building, PWH

Primary sponsor's address:

Department of Paediatrics, 6/F Clinical Sciences Building, PWH

试验主办单位(项目批准或申办者):

Secondary sponsor:

经费或物资来源:

Department of Paediatrics, CUHK

Source(s) of funding:

Department of Paediatrics, CUHK

研究疾病:

Parenteral nutrition-associated cholestasis in infants  

Target disease:

Parenteral nutrition-associated cholestasis in infants

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

Omegaven for rescue treatment of parenteral nutrition-associated cholestasis (PNAC) in infants requiring long-term parenteral nutrition  

Objectives of Study:

Omegaven for rescue treatment of parenteral nutrition-associated cholestasis (PNAC) in infants requiring long-term parenteral nutrition

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1. major congenital or lethal chromosomal abnormalities;
2. multiorgan failure and imminent death;
3. cholestatic jaundice secondary to other known causes e.g., congenital or acquired TORCH and syphillis infection; hepatitis B and C infection; biliary atresia and other lesions obstructing bile flow, both intrahepatic and extrahepatic

Exclusion criteria:

1. major congenital or lethal chromosomal abnormalities;
2. multiorgan failure and imminent death;
3. cholestatic jaundice secondary to other known causes e.g., congenital or acquired TORCH and syphillis infection; hepatitis B and C infection; biliary atresia and other lesions obstructing bile flow, both intrahepatic and extrahepatic

研究实施时间:

Study execute time:

From 2008-04-30 00:00:00 To 2013-05-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2008-04-30 00:00:00 To 2013-05-31 00:00:00

干预措施:

Interventions:

组别:

Two groups

样本量:

54

Group:

Two groups

Sample size:

干预措施:

Omegaven (fish oil-based parenteral lipid supplement) vs Intralipid (soy-based parenteral lipid supplement) at least 4 months

干预措施代码:

Intervention:

Omegaven (fish oil-based parenteral lipid supplement) vs Intralipid (soy-based parenteral lipid supplement) at least 4 months

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中國

省(直辖市):

香港特別行政區 

市(区县):

 

Country:

China

Province:

Hong Kong SAR

City:

单位(医院):

Chinese University of Hong Kong 

单位级别:

Chinese University of Hong Kong 

Institution
hospital:

Chinese University of Hong Kong

Level of the institution:

Chinese University of Hong Kong

测量指标:

Outcomes:

指标中文名:

Infant growth; blood lipid profile; coagulation status; episodes of late-onset infection over 4 months.

指标类型:

次要指标

Outcome:

Infant growth; blood lipid profile; coagulation status; episodes of late-onset infection over 4 months.

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

Reversal of PNAC over 4 months

指标类型:

主要指标

Outcome:

Reversal of PNAC over 4 months

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 0 years
最大 Max age 12 years

性别:

男性

Gender:

Male

随机方法(请说明由何人用什么方法产生随机序列):

randomized

Randomization Procedure (please state who generates the random number sequence and by what method):

Randomized, Active control, Double-blind, Parallel groups

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

Double-blind

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

数据与安全监察委员会:

Data and Safety Monitoring Committee:

注册人:

Name of Registration:

 2015-06-02 21:47:48